AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives

Overview of attention for article published in Orphanet Journal of Rare Diseases, June 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 2,645 followers.

A deeper dive scientific analysis of AAV-vector based gene therapy retinal disease LCA where Luxturna has/is the only treatment to be approved by the FDA. Understanding #OCU400 is differentiated by its ‘gene agnostic’ multi-faceted application. https://t

10 May 2024

Reply Repost Favourite

Check out this review paper on #AAV gene therapy for mitochondrial disease by our former lab member, @AllisonHPhD: https://t.co/op8DYeX6GG

08 Sep 2022

Reply Repost Favourite

AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives https://t.co/JOoRZnZFOJ

08 Jun 2022

Reply Repost Favourite

AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives https://t.co/KUtZujg16B https://t.co/WAH60kjFjN

07 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.